Recursion Pharmaceuticals Financial Statements
NASDAQ: RXRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Recursion Pharmaceuticals revenue and earnings
In fiscal 2025, Recursion Pharmaceuticals generated $74.7 million in revenue, up 26.9% from fiscal 2024, its 6th consecutive year of revenue growth. Recursion Pharmaceuticals reported a net loss of $644.8 million, compared with a loss of $463.7 million a year earlier. Gross margin was 5.0% (down from 23.1%) and operating margin -867.9%.
Diluted earnings per share came in at -$1.44. Over the last 5 fiscal years, RXRX's revenue has grown at a 79.9% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Recursion Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Revenue | 74.68M | 58.84M | 44.58M | 39.84M | 10.18M | 3.96M | 2.32M |
| Revenue growth (YoY) | +26.92% | +32.00% | +11.88% | +291.46% | +156.89% | +70.85% | — |
| Cost of Revenue | 70.95M | 45.24M | 42.59M | 48.27M | 0 | 0 | — |
| Gross Profit | 3.73M | 13.60M | 1.99M | -8.43M | 10.18M | 3.96M | — |
| Operating Expenses | 651.86M | 492.61M | 352.05M | 237.29M | 192.95M | 88.58M | 64.76M |
| Research & Development | 475.27M | 314.42M | 241.23M | 155.70M | 135.27M | 63.32M | 45.81M |
| Operating Income | -648.13M | -479.00M | -350.06M | -245.73M | -182.78M | -84.61M | -62.44M |
| Interest Expense | 1.81M | 1.57M | 97.00K | 55.00K | 2.95M | 1.36M | 635.00K |
| Other Income (Expense) | 3.24M | 14.22M | 17.93M | 6.25M | -3.70M | -2.39M | 562.00K |
| Pretax Income | -644.89M | -464.79M | -332.13M | -239.48M | -186.48M | — | — |
| Income Tax | -136.00K | -1.13M | -4.06M | 0 | 0 | 0 | 0 |
| Net Income | -644.76M | -463.66M | -328.07M | -239.48M | -186.48M | -87.01M | -61.88M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| EPS (Basic) | -1.44 | -1.69 | -1.58 | -1.36 | -1.49 | -3.99 | -2.87 |
| EPS (Diluted) | -1.44 | -1.69 | -1.58 | -1.36 | -1.49 | -3.99 | -2.87 |
| Shares Outstanding (Basic) | 447.45M | 274.21M | 207.85M | 175.54M | 125.35M | 21.78M | 21.57M |
| Shares Outstanding (Diluted) | 447.45M | 274.21M | 207.85M | 175.54M | 125.35M | 21.78M | 21.57M |
| EBITDA | -564.43M | -442.51M | -325.66M | -233.97M | -174.37M | -80.67M | -59.95M |
| Gross Margin | 4.99% | 23.12% | 4.46% | -21.16% | 100.00% | 100.00% | — |
| Operating Margin | -867.87% | -814.09% | -785.33% | -616.74% | -1795.79% | -2135.66% | -2692.58% |
| Net Margin | -863.35% | -788.02% | -735.99% | -601.05% | -1832.18% | -2196.01% | -2668.35% |
This table shows 7 annual periods of Recursion Pharmaceuticals's income statement, from FY 2025 back to FY 2019, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow RXRX's reporting calendar. What is a income statement?